#USA #CARY #Veloxis Pharmaceuticals #Envarsus XR #AIC468

Veloxis Pharmaceuticals Showcases Research at the 2026 American Transplant Congress

Veloxis Pharmaceuticals, Inc., a subsidiary of Asahi Kasei Corporation based in Cary, North Carolina, is making significant advancements in transplant medicine. At the upcoming American Transplant Congress (ATC) from June 20-24, 2026, in Boston, Massachusetts, Veloxis will present five notable research findings through poster sessions. These presentations highlight the company's commitment to improving the lives of patients who have undergone transplantation and those who are immunocompromised.

Presentation Highlights

The ATC will feature three posters focused on real-world health economics and outcomes research, as well as a pivotal post-hoc analysis of a Phase 3b trial. Furthermore, a key presentation will cover a Phase 1 study investigating the safety and pharmacokinetics of a novel therapy, AIC468, specifically targeting BK virus infections in adult kidney transplant patients.

Key Details of the Presentations

1. Posttransplant Outcomes with Envarsus XR vs. Immediate-Release Tacrolimus in Adult Liver Transplant Recipients in the US
Presenter: Lobat Hashemi
Date and Time: June 20, 2026, 5:45 PM - 6:45 PM EST

2. Comparison of Female and Male Adult Liver Transplant Recipients Prescribed Envarsus XR and Immediate-Release Tacrolimus for Maintenance Immunosuppression in the US
Presenter: Lobat Hashemi
Date and Time: June 20, 2026, 5:45 PM - 6:45 PM EST

3. Safety and Pharmacokinetics in Healthy Volunteers Following Single and Multiple Ascending Doses of AIC468
Presenter: Kenneth Lawrence
Date and Time: June 20, 2026, 5:45 PM - 6:45 PM EST

4. Physician-Patient Discordance in Symptom Reporting Post-Kidney Transplant: Evidence from a Real-World Survey
Presenter: Lobat Hashemi
Date and Time: June 22, 2026, 2:45 PM - 3:45 PM EST

5. Concordance Between C/D Ratio and Cyp3A5 Genotype in African American Kidney Transplant Recipients Receiving Immediate-Release Tacrolimus
Presenter: Timothy A. Horwedel
Date and Time: June 23, 2026, 2:30 PM - 3:30 PM EST

Commitment to Transplant Medicine

Veloxis Pharmaceuticals is dedicated to tackling unmet needs in transplant medicine and addressing issues that affect both transplant recipients and healthcare providers. The company is committed to developing and commercializing innovative treatments tailored specifically for immunocompromised patients.

About Veloxis Pharmaceuticals

As part of Asahi Kasei, Veloxis is well-positioned in the global pharmaceutical landscape, particularly focusing on areas of serious medical need. The company applies its resources and expertise to enhance survival rates and quality of life for organ transplant recipients.

For anyone seeking more details about Veloxis Pharmaceuticals and their innovative solutions, additional information can be found at Veloxis.com.

In Closing

Veloxis Pharmaceuticals' participation at the 2026 American Transplant Congress underscores its commitment to advancing transplant patient care through research and innovation. By sharing these critical findings, they aim to foster a greater understanding of the complexities involved in post-transplant patient management and contribute to ongoing discussions in the field.